Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy

Cathy M. McGeough, Daniel Berrar, Gary Wright, Clare Mathews, Paula Gilmore, Rodat T. Cunningham, Anthony J. Bjourson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The identification of patients who will respond to anti-tumor necrosis factor alpha (anti-TNF-α) therapy will improve the efficacy, safety, and economic impact of these agents. We investigated whether killer cell immunoglobulin- like receptor (KIR) genes are related to response to anti-TNF-α therapy in patients with rheumatoid arthritis (RA). Sixty-four RA patients and 100 healthy controls were genotyped for 16 KIR genes and human leukocyte antigen-C (HLA-C) group 1/2 using polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP). Each patient received anti-TNF-α therapy (adalimumab, etanercept, or infliximab), and clinical responses were evaluated after 3 months using the disease activity score in 28 joints (DAS28). We investigated the correlations between the carriership of KIR genes, HLA-C group 1/2 genes, and clinical data with response to therapy. Patients responding to therapy showed a significantly higher frequency of KIR2DS2/KIR2DL2 (67.7% R vs. 33.3% NR; P = 0.012). A positive clinical outcome was associated with an activating KIR-HLA genotype; KIR2DS2+HLA-C group 1/2 homozygous. Inversely, nonresponse was associated with the relatively inhibitory KIR2DS2-HLA-C group 1/2 heterozygous genotype. The KIR and HLA-C genotype of an RA patient may provide predictive information for response to anti-TNF-α therapy.

Original languageEnglish
Pages (from-to)1647-1653
Number of pages7
JournalRheumatology International
Volume32
Issue number6
DOIs
Publication statusPublished - 2012 Jun
Externally publishedYes

Keywords

  • Anti-TNF-αlpha therapy
  • Genotype
  • Human leukocyte antigen-C
  • Killer immunoglobulin-like receptor
  • Natural killer cells
  • Responder
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. / McGeough, Cathy M.; Berrar, Daniel; Wright, Gary; Mathews, Clare; Gilmore, Paula; Cunningham, Rodat T.; Bjourson, Anthony J.

In: Rheumatology International, Vol. 32, No. 6, 06.2012, p. 1647-1653.

Research output: Contribution to journalArticle

McGeough, Cathy M. ; Berrar, Daniel ; Wright, Gary ; Mathews, Clare ; Gilmore, Paula ; Cunningham, Rodat T. ; Bjourson, Anthony J. / Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. In: Rheumatology International. 2012 ; Vol. 32, No. 6. pp. 1647-1653.
@article{bd21af3414674946904af22b0afccee8,
title = "Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy",
abstract = "The identification of patients who will respond to anti-tumor necrosis factor alpha (anti-TNF-α) therapy will improve the efficacy, safety, and economic impact of these agents. We investigated whether killer cell immunoglobulin- like receptor (KIR) genes are related to response to anti-TNF-α therapy in patients with rheumatoid arthritis (RA). Sixty-four RA patients and 100 healthy controls were genotyped for 16 KIR genes and human leukocyte antigen-C (HLA-C) group 1/2 using polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP). Each patient received anti-TNF-α therapy (adalimumab, etanercept, or infliximab), and clinical responses were evaluated after 3 months using the disease activity score in 28 joints (DAS28). We investigated the correlations between the carriership of KIR genes, HLA-C group 1/2 genes, and clinical data with response to therapy. Patients responding to therapy showed a significantly higher frequency of KIR2DS2/KIR2DL2 (67.7{\%} R vs. 33.3{\%} NR; P = 0.012). A positive clinical outcome was associated with an activating KIR-HLA genotype; KIR2DS2+HLA-C group 1/2 homozygous. Inversely, nonresponse was associated with the relatively inhibitory KIR2DS2-HLA-C group 1/2 heterozygous genotype. The KIR and HLA-C genotype of an RA patient may provide predictive information for response to anti-TNF-α therapy.",
keywords = "Anti-TNF-αlpha therapy, Genotype, Human leukocyte antigen-C, Killer immunoglobulin-like receptor, Natural killer cells, Responder, Rheumatoid arthritis",
author = "McGeough, {Cathy M.} and Daniel Berrar and Gary Wright and Clare Mathews and Paula Gilmore and Cunningham, {Rodat T.} and Bjourson, {Anthony J.}",
year = "2012",
month = "6",
doi = "10.1007/s00296-011-1838-6",
language = "English",
volume = "32",
pages = "1647--1653",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy

AU - McGeough, Cathy M.

AU - Berrar, Daniel

AU - Wright, Gary

AU - Mathews, Clare

AU - Gilmore, Paula

AU - Cunningham, Rodat T.

AU - Bjourson, Anthony J.

PY - 2012/6

Y1 - 2012/6

N2 - The identification of patients who will respond to anti-tumor necrosis factor alpha (anti-TNF-α) therapy will improve the efficacy, safety, and economic impact of these agents. We investigated whether killer cell immunoglobulin- like receptor (KIR) genes are related to response to anti-TNF-α therapy in patients with rheumatoid arthritis (RA). Sixty-four RA patients and 100 healthy controls were genotyped for 16 KIR genes and human leukocyte antigen-C (HLA-C) group 1/2 using polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP). Each patient received anti-TNF-α therapy (adalimumab, etanercept, or infliximab), and clinical responses were evaluated after 3 months using the disease activity score in 28 joints (DAS28). We investigated the correlations between the carriership of KIR genes, HLA-C group 1/2 genes, and clinical data with response to therapy. Patients responding to therapy showed a significantly higher frequency of KIR2DS2/KIR2DL2 (67.7% R vs. 33.3% NR; P = 0.012). A positive clinical outcome was associated with an activating KIR-HLA genotype; KIR2DS2+HLA-C group 1/2 homozygous. Inversely, nonresponse was associated with the relatively inhibitory KIR2DS2-HLA-C group 1/2 heterozygous genotype. The KIR and HLA-C genotype of an RA patient may provide predictive information for response to anti-TNF-α therapy.

AB - The identification of patients who will respond to anti-tumor necrosis factor alpha (anti-TNF-α) therapy will improve the efficacy, safety, and economic impact of these agents. We investigated whether killer cell immunoglobulin- like receptor (KIR) genes are related to response to anti-TNF-α therapy in patients with rheumatoid arthritis (RA). Sixty-four RA patients and 100 healthy controls were genotyped for 16 KIR genes and human leukocyte antigen-C (HLA-C) group 1/2 using polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP). Each patient received anti-TNF-α therapy (adalimumab, etanercept, or infliximab), and clinical responses were evaluated after 3 months using the disease activity score in 28 joints (DAS28). We investigated the correlations between the carriership of KIR genes, HLA-C group 1/2 genes, and clinical data with response to therapy. Patients responding to therapy showed a significantly higher frequency of KIR2DS2/KIR2DL2 (67.7% R vs. 33.3% NR; P = 0.012). A positive clinical outcome was associated with an activating KIR-HLA genotype; KIR2DS2+HLA-C group 1/2 homozygous. Inversely, nonresponse was associated with the relatively inhibitory KIR2DS2-HLA-C group 1/2 heterozygous genotype. The KIR and HLA-C genotype of an RA patient may provide predictive information for response to anti-TNF-α therapy.

KW - Anti-TNF-αlpha therapy

KW - Genotype

KW - Human leukocyte antigen-C

KW - Killer immunoglobulin-like receptor

KW - Natural killer cells

KW - Responder

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84863880925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863880925&partnerID=8YFLogxK

U2 - 10.1007/s00296-011-1838-6

DO - 10.1007/s00296-011-1838-6

M3 - Article

VL - 32

SP - 1647

EP - 1653

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 6

ER -